Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

• প্রধান লেখক: Xiaomin Wan (লেখক), Xiaohui Zeng (লেখক), Liubao Peng (লেখক), Ye Peng (লেখক), Qiao Liu (লেখক), Lidan Yi (লেখক), Xia Luo (লেখক), Qijian Deng (লেখক), Chongqing Tan (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective.Materials and methods: A Markov model wasdeveloped to evaluate the cost and effec...